Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients With Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study.
Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients With Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study.
复制标题
互补的中草药疗法可改善台湾胰腺癌患者的生存：一项基于人群的同类研究。
DOI：
10.1177/1534735417722224
复制
发表时间：
2018-06
影响因子：
2.9
通讯作者：
Yen HR
中科院分区：
文献类型：
--
作者：
Kuo YT;Liao HH;Chiang JH;Wu MY;Chen BC;Chang CM;Yeh MH;Chang TT;Sun MF;Yeh CC;Yen HR
背景：胰腺癌是临床表现较晚、预后较差的难治性癌症。一些患者寻求中医咨询。本研究旨在探讨中草药辅助性治疗对台湾胰腺癌患者之益处。方法：我们纳入了1997-2010年间在台湾灾难性疾病患者数据库登记的所有胰腺癌患者。我们采用1：1的频率匹配方法，按年龄、性别、胰腺癌的初始诊断年份和指数年份进行配对，共登记了386名中医使用者和386名非中医使用者。用Cox回归模型比较死亡风险的危险比(HR)。生存时间比较采用Kaplan-Meier曲线。结果：根据COX风险比模型对中药使用、年龄、性别、城市化水平、合并症和治疗进行相互调整，发现中药使用者的死亡风险风险较低(调整后的HR=0.67，95%CI=0.56~0.79)。接受中药治疗90天以上的患者死亡风险风险比显著低于非中药使用者(90-180天组：调整后的HR=0.56，95%CI=0.42-0.75；180天组：HR=0.33，95%CI=0.24-0.45)。中医组患者的生存概率较高。白花蛇舌草(白花蛇舌草，白花蛇舌草)和香砂六君子汤(白花蛇舌草、白花蛇舌草、白花蛇舌草)分别是白花蛇舌草和香砂六君子汤中最常用的单味药和方剂。结论：中药辅助治疗可能与降低胰腺癌患者的死亡率有关。进一步的前瞻性临床试验是有必要的。
Background: Pancreatic cancer is a difficult-to-treat cancer with a late presentation and poor prognosis. Some patients seek traditional Chinese medicine (TCM) consultation. We aimed to investigate the benefits of complementary Chinese herbal medicine (CHM) among patients with pancreatic cancer in Taiwan. Methods: We included all patients with pancreatic cancer who were registered in the Taiwanese Registry for Catastrophic Illness Patients Database between 1997 and 2010. We used 1:1 frequency matching by age, sex, the initial diagnostic year of pancreatic cancer, and index year to enroll 386 CHM users and 386 non-CHM users. A Cox regression model was used to compare the hazard ratios (HRs) of the risk of mortality. The Kaplan-Meier curve was used to compare the difference in survival time. Results: According to the Cox hazard ratio model mutually adjusted for CHM use, age, sex, urbanization level, comorbidity, and treatments, we found that CHM users had a lower hazard ratio of mortality risk (adjusted HR = 0.67, 95% CI = 0.56-0.79). Those who received CHM therapy for more than 90 days had significantly lower hazard ratios of mortality risk than non-CHM users (90- to 180-day group: adjusted HR = 0.56, 95% CI = 0.42-0.75; >180-day group: HR = 0.33, 95% CI = 0.24-0.45). The survival probability was higher for patients in the CHM group. Bai-hua-she-she-cao (Herba Oldenlandiae; Hedyotis diffusa Spreng) and Xiang-sha-liu-jun-zi-tang (Costus and Chinese Amomum Combination) were the most commonly used single herb and Chinese herbal formula, respectively. Conclusions: Complementary Chinese herbal therapy might be associated with reduced mortality among patients with pancreatic cancer. Further prospective clinical trial is warranted.
登录
查看更多内容
影响因子：
3
作者：
Saif, Muhammad Wasif;Li, Jia;Lamb, Lynne;Kaley, Kristin;Elligers, Kyle;Jiang, Zaoli;Bussom, Scott;Liu, Shwu-Huey;Cheng, Yung-Chi
通讯作者：
Cheng, Yung-Chi
影响因子：
4
作者：
Fleischer T;Chang TT;Chiang JH;Chang CM;Hsieh CY;Yen HR
通讯作者：
Yen HR
影响因子：
2.9
作者：
Riedlinger, JE;Tan, PW;Lu, WD
通讯作者：
Lu, WD
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
5.2
作者：
Lin, Jiumao;Wei, Lihui;Peng, Jun
通讯作者：
Peng, Jun